



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Königsberg, A;Sehner, S;Arlt, S;Cheng, B;Simonsen, CZ;Boutitie, F;Serena, J;Thijs, V;Ebinger, M;Endres, M;Fiebach, JB;Lemmens, R;Muir, KW;Nighoghossian, N;Pedraza, S;Gerloff, C;Thomalla, G

Title:

Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial

Date:

2021-06-01

Citation:

Königsberg, A., Sehner, S., Arlt, S., Cheng, B., Simonsen, C. Z., Boutitie, F., Serena, J., Thijs, V., Ebinger, M., Endres, M., Fiebach, J. B., Lemmens, R., Muir, K. W., Nighoghossian, N., Pedraza, S., Gerloff, C. & Thomalla, G. (2021). Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial. *European Journal of Neurology*, 28 (6), pp.2017-2025. <https://doi.org/10.1111/ene.14797>.

Persistent Link:


<https://hdl.handle.net/11343/280260>

License:

[CC BY-NC-ND](#)

## ORIGINAL ARTICLE

# Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial

Alina Königsberg<sup>1</sup>  | Susanne Sehner<sup>2</sup> | Sönke Arlt<sup>3</sup> | Bastian Cheng<sup>1</sup> |  
Claus Z. Simonsen<sup>4</sup> | Florent Boutitie<sup>5</sup> | Joaquin Serena<sup>6</sup> | Vincent Thijs<sup>7,8</sup> |  
Martin Ebinger<sup>9,10</sup> | Matthias Endres<sup>9,11,12</sup> | Jochen B. Fiebach<sup>9</sup> | Robin Lemmens<sup>13,14,15</sup> |  
Keith W. Muir<sup>16</sup> | Norbert Nighoghossian<sup>17</sup>  | Salvador Pedraza<sup>18</sup> | Christian Gerloff<sup>1</sup> |  
Götz Thomalla<sup>1</sup> | the WAKE-UP investigators

<sup>1</sup>Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

<sup>2</sup>Institut für Medizinische Biometrie und Epidemiologie, Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

<sup>3</sup>Department of Psychiatry and Psychotherapy, Evangelical Hospital Alsterdorf, Hamburg, Germany

<sup>4</sup>Department of Neurology, Aarhus University Hospital, Aarhus, Denmark

<sup>5</sup>Service de Biostatistique, Centre d'Investigation Clinique, Hospices Civils de Lyon, Lyon, France

<sup>6</sup>Department of Neurology, Hospital Universitario Dr Josep Trueta, Institut d'Investigació Biomèdica de Girona, Girona, Spain

<sup>7</sup>Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia

<sup>8</sup>Department of Neurology, Austin Health, Heidelberg, Victoria, Australia

<sup>9</sup>Centrum für Schlaganfallforschung Berlin (CSB), Charité-Universitätsmedizin Berlin, Berlin, Germany

<sup>10</sup>Klinik für Neurologie, Medical Park Berlin Humboldtstraße, Berlin, Germany

<sup>11</sup>Klinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin Berlin, Berlin, Germany

<sup>12</sup>Exzellenz Cluster Neuro Cure, Charité-Universitätsmedizin Berlin, Berlin, Germany, DZHK, partner site Berlin, DZNE, partner site Berlin, Berlin, Germany

<sup>13</sup>Department of Neurology, University Hospitals Leuven, Leuven, Belgium

<sup>14</sup>Vesalius Research Center, VIB, Leuven, Belgium

<sup>15</sup>Experimental Neurology and Leuven Research Institute for Neurodegenerative Diseases (LIND), University of Leuven, Leuven, Belgium

<sup>16</sup>Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK

<sup>17</sup>Department of Neurology, Hospices Civils de Lyon, Lyon, France

<sup>18</sup>Department of Radiology, Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain

## Correspondence

Alina Königsberg, Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.  
Email: a.koenigsberg@uke.de

## Funding information

WAKE-UP received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no.278276 (WAKE-UP).

## Abstract

**Background and purpose:** The aim was to study the effect of intravenous alteplase on the development of post-stroke depression (PSD) in acute stroke patients, and to identify predictors of PSD.

**Methods:** This post hoc analysis included patients with unknown onset stroke randomized to treatment with alteplase or placebo in the WAKE-UP trial (ClinicalTrials.gov number, NCT01525290), in whom a composite end-point of PSD was defined as a Beck Depression Inventory  $\geq 10$ , medication with an antidepressant, or depression recorded as an adverse event. Multiple logistic regression was used to identify predictors of PSD at

**Abbreviations:** BDI, Beck Depression Inventory; CDE, controlled direct effect; CI, confidence interval; IQR, interquartile range; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; NIE, natural indirect effect; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; PSD, post-stroke depression; SAE, serious adverse event; SD, standard deviation.

See commentary by M. Diomedes and I. Maestrini on page 1799

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. *European Journal of Neurology* published by John Wiley & Sons Ltd on behalf of European Academy of Neurology

90 days. Structural equation modelling was applied to assess the indirect effect of thrombolysis on PSD mediated by the modified Rankin Scale.

**Results:** Information on the composite end-point was available for 438 of 503 randomized patients. PSD was present in 96 of 224 (42.9%) patients in the alteplase group and 115 of 214 (53.7%) in the placebo group (odds ratio 0.63; 95% confidence interval 0.43–0.94;  $p = 0.022$ ; adjusted for age and National Institutes of Health Stroke Scale at baseline). Prognostic factors associated with PSD included baseline medication with antidepressants, higher lesion volume, history of depression and assignment to placebo. While 65% of the effect of thrombolysis on PSD were caused directly, 35% were mediated by an improvement of the mRS.

**Conclusions:** Treatment with alteplase in patients with acute stroke resulted in lower rates of depression at 90 days, which were only partially explained by reduced functional disability. Predictors of PSD including history and clinical characteristics may help in identifying patients at risk of PSD.

#### KEYWORDS

DWI, MRI, WAKE-UP

## INTRODUCTION

Post-stroke depression (PSD) is a frequent complication after acute stroke with reported prevalence ranging from 29% to 43% [1-4]. PSD impairs recovery from stroke, in particular cognitive and motor function, and negatively affects quality of life after stroke [5]. Several studies have attempted to identify predictive factors of PSD with heterogeneous results. Factors found to be associated with PSD comprise socio-demographic factors such as female sex [2], genetic factors like serotonin transporter gene polymorphisms [6], stroke-associated factors like disability [7], symptom severity or stroke location [8], or history of mood disorders and mild cognitive impairment [9], and depression and cognitive dysfunction at baseline [10].

Intravenous thrombolysis with alteplase is the standard of care for acute ischaemic stroke and improves functional outcome as well as quality of life [11,12]. The potential effect of thrombolysis on PSD, however, has not yet been investigated in the setting of a randomized controlled trial, and there are only few data from observational studies with heterogeneous findings [7,13].

The aim was to investigate the effect of intravenous alteplase on PSD 3 months after stroke in the WAKE-UP trial (efficacy and safety of magnetic resonance imaging [MRI] based thrombolysis in wake-up stroke: a randomized, double-blind, placebo-controlled trial), and to test whether there is an effect on PSD not captured by the traditional measurement of functional outcome. Moreover, the aim was to identify predictors of PSD.

## METHODS

This is a post hoc analysis of included patients with unknown onset stroke randomized to treatment with alteplase or placebo

in the WAKE-UP trial. WAKE-UP was a multicentre, randomized, double-blind, placebo-controlled clinical trial of MRI-based intravenous thrombolysis in unknown onset stroke. The trial protocol and main results have been published previously [14]. Briefly, patients with acute ischaemic stroke of unknown onset that represented with a mismatch between an acute ischaemic lesion visible on diffusion-weighted imaging but no marked parenchymal hyperintensity in the corresponding region on fluid-attenuated inversion recovery, and who otherwise met clinical inclusion and exclusion criteria for intravenous alteplase, were randomized to receive either alteplase or placebo. Primary outcome was a favourable outcome at 90 days after stroke defined as a score of 0 or 1 assessed on the modified Rankin Scale (mRS). Among the secondary outcome measures, depressive symptoms at 90 days after stroke were assessed using the Beck Depression Inventory (BDI), a 21-item scale asking for depressive symptoms with a four-point rating (0–3) for each item based on the severity of each item, adding up to a total score of 0–63. For this secondary analysis, all randomized patients for whom a completed language-specific BDI questionnaire in each participating country at 90 days was available were included.

### Study outcomes—post-stroke depression

For the present analysis PSD was investigated as a composite end-point, defined by any depression according to the BDI at 90 days following the established threshold of  $\geq 10$  [15-17], depression recorded as a serious adverse event (SAE), or the use of antidepressants in concomitant medication up to 90 days after stroke. As it cannot be ruled out that antidepressants were given to patients for other reasons than depression, an additional sensitivity analysis

was performed with the combined end-point of a BDI of  $\geq 10$  or depression as an SAE, disregarding the use of antidepressants.

## Statistical analysis

Sample characteristics are given as absolute and relative frequencies or mean  $\pm$  standard deviation as well as median with interquartile range, whichever is appropriate. Statistical analysis of the treatment effect of alteplase on PSD was performed in the intention-to-treat population for all patients with available information for the composite end-point PSD (BDI  $\geq 10$ , medication with an antidepressant, or depression recorded as an SAE) and a secondary composite end-point composed of BDI  $\geq 10$  or SAE.

The effect of treatment on PSD was estimated using a multiple logistic regression model adjusted for age and National Institutes of Health Stroke Scale (NIHSS) at baseline. To identify possible predictors of PSD, three multiple logistic regression models were fitted with the composite end-point of PSD as dependent variable and three sets of baseline variables as predictors. In the first model, only age, NIHSS and treatment (alteplase/placebo) were included as predictors. In a second model, sex, baseline medication (antidepressant/other psychiatric medication), depression in medical history and hemisphere of stroke lesion were added. Finally, in a third model stroke lesion volume after 22–36 h was further added which was included as the base-2 logarithm of its third root due to its skewed distribution. For all models odds ratios (ORs) with corresponding 95% confidence intervals (95% CIs) were reported.

As thrombolysis is known to ameliorate functional outcome after stroke, it was hypothesized that better functional outcome may be the main reason for lower rates of depression in the alteplase group. To evaluate the role of the functional outcome variable mRS as a potential mediator of the relationship between treatment and PSD, a mediation analysis was performed with PSD as dependent variable, mRS as the mediator, treatment with alteplase or placebo as predictor, and age and NIHSS as covariates using structural equation models [18,19] within Stata 16.0 (StataCorp. 2019, Stata Statistical Software: Release 16, College Station, TX, USA, StataCorp LLC) and the PARAMED package [20]. The results are visualized by forest plots showing effects with corresponding 95% CI.

All of the models present analyses of cases with available information. A two-tailed  $p < 0.05$  was considered to be statistically significant. Nominal  $p$  values are reported without correction for multiplicity.

## RESULTS

Of 503 randomized patients, 438 (87%) patients had information on PSD available. Of these, 224 were assigned to alteplase and 214 to placebo. Baseline and outcome variables are displayed in Table 1. For 65 patients, no information on depression as an SAE or medication or BDI was available. These patients had higher baseline median NIHSS scores compared to patients with all information available

(7 vs. 5,  $p = 0.023$ ), higher median mRS scores at 90 days (3 vs. 2,  $p < 0.001$ ) and less often antidepressant medication prescribed at baseline (0% vs. 8.9%,  $p = 0.009$ ), while other baseline and outcome variables did not differ significantly between the two groups.

The BDI and mRS correlated moderately with each other (Spearman correlation coefficient 0.42,  $p < 0.001$ ). The percentage of patients with and without depression according to the composite end-point PSD, stratified by mRS, is depicted in Figure 1.

## Effect of alteplase on the post-stroke depression composite end-point

Treatment with alteplase was associated with significantly lower rates of PSD, observed in 96 of 224 (42.9%) patients in the alteplase group compared to 115 of 214 (53.7%) patients in the placebo group (age and NIHSS adjusted OR 0.63; 95% CI 0.43–0.94;  $p = 0.022$ ) (cf. Figure 2).

In the sensitivity analysis of the composite end-point, information on depression was available for 424 patients. Also after excluding the intake of antidepressants from the definition, PSD was observed less frequently in the alteplase group with 79 of 219 (36.1%) patients than in the placebo group with 95 of 205 (46.3%) patients (adjusted OR 0.63; 95% CI 0.42–0.93,  $p = 0.023$ ).

## Predictors of post-stroke depression at 90 days

In the simple model, NIHSS at baseline (OR 1.13, 95% CI 1.08–1.18,  $p < 0.001$ ) and treatment with placebo (OR 1.58, 95% CI 1.07–2.34,  $p = 0.022$ ) were significant predictors of PSD. In the model with additional baseline parameters but without adjustment for stroke lesion volume, higher NIHSS score at baseline (OR 1.12, 95% CI 1.07–1.17,  $p < 0.001$ ), baseline medication with antidepressants (OR 4.55, 95% CI 1.45–14.31,  $p = 0.010$ ) and treatment with placebo (OR 1.72, 95% CI 1.13–2.62,  $p = 0.012$ ) were significant predictors of PSD. In the full model, stroke lesion volume (OR 2.24, 95% CI 1.62–3.12,  $p < 0.001$ ), history of depression (OR 6.54, 95% CI 1.04–41.17,  $p = 0.045$ ), medication with antidepressants (OR 6.10, 95% CI 1.72–21.67,  $p = 0.005$ ) and treatment with placebo (OR 1.70, 95% CI 1.07–2.68,  $p = 0.024$ ) were significant predictors of PSD 90 days after stroke (cf. Table 2, Figure 3).

## Effects of alteplase on functional outcome and post-stroke depression—structural equation modelling

In structural equation modelling without adjustment for age and NIHSS, the total effect of treatment with alteplase was negatively associated with the probability of PSD (0.61, 95% CI 0.39–0.96,  $p = 0.031$ ). Of this total effect, a 41% proportion was mediated by the natural indirect effect (NIE), that is, an improvement of the mRS. A higher mRS was significantly associated with a higher probability of PSD (OR 2.0, 95% CI 1.67–2.38,  $p < 0.001$ ), and treatment with alteplase reduced the mRS significantly by a mean


**TABLE 1** Baseline and outcome variables of both treatment groups

Variables	Patients with available information on the composite end-point PSD (N = 438)		
	Placebo group	Alteplase group	p value
	N = 214	N = 224	
Age in years, mean $\pm$ SD	65.1 $\pm$ 11.6	64.7 $\pm$ 11.2	0.71
Sex = male	132 (61.7%)	150 (67.0%)	0.249
NIHSS, median (IQR)	5.0 (4.0–9.0)	5.0 (3.0–9.0)	0.635
Lesion volume at baseline in ml, median (IQR)	2.6 (0.8–9.0)	1.8 (0.7–7.8)	0.324
Missing	3 (1.4%)	6 (2.7%)	
Lesion volume at 22–36 h in ml, median (IQR)	3.4 (1.2–16.8)	3.0 (1.0–18.2)	0.401
Missing	17 (7.9%)	28 (12.5%)	
Lacunar stroke	44 (20.6%)	48 (21.4%)	0.52
Missing	168 (78.5%)	175 (78.1%)	
Infratentorial stroke	22 (10.3%)	25 (11.2%)	0.601
Missing	17 (7.9%)	30 (13.4%)	
Hemisphere			
Left	107 (50.0%)	117 (52.2%)	0.005
Right	94 (43.9%)	76 (33.9%)	
Bilateral	6 (2.8%)	21 (9.4%)	
Missing	7 (3.3%)	10 (4.5%)	
History of depression	12 (5.6%)	14 (6.3%)	0.785
Missing	1 (0.5%)		
History of other psychiatric disease	1 (0.5%)	5 (2.2%)	0.097
Missing	1 (0.5%)		
Baseline medication with antidepressant	20 (9.3%)	19 (8.5%)	0.739
Missing	1 (0.5%)		
Baseline medication with other psychiatric drug	10 (4.7%)	11 (4.9%)	0.916
Missing	1 (0.5%)		
At 90 days			
mRS, median (IQR)	2.0 (1.0–3.0)	1.0 (1.0–2.0)	0.018
Missing	2 (1.0%)	1 (0.5%)	
BDI at 90 days, median (IQR)	7.0 (2.0–14.0)	6.0 (2.0–11.0)	0.14
Missing	13 (6.1%)	11 (4.9%)	

**TABLE 1** (Continued)

Variables	Patients with available information on the composite end-point PSD (N = 438)		
	Placebo group	Alteplase group	p value
	N = 214	N = 224	
Any depression (BDI $\geq$ 10)	79 (30.4%)	65 (29.0%)	0.061
Missing	13 (6.1%)	11 (4.9%)	
Medication with an antidepressant	68 (31.8%)	54 (24.1%)	0.069
Missing	1 (0.5%)		
SAE depression	27 (12.6%)	21 (9.4%)	0.27
Missing	1 (0.5%)		
PSD	115 (53.7%)	96 (42.9%)	0.023

Abbreviations: BDI, Beck Depression Inventory; IQR, interquartile range; mRS, modified Rankin Scale; n, number of patients; NIHSS, National Institutes of Health Stroke Scale; PSD, post-stroke depression; SAE, serious adverse event; SD, standard deviation.




**FIGURE 1** Percentage of patients with depression according to the composite end-point of post-stroke depression (PSD), stratified by mRS at day 90. Numbers on the columns indicate absolute patient numbers, column sizes correspond to the percentage of patients with regard to one mRS value [Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

of 0.29 points (95% CI for reduction 0.03–0.56,  $p = 0.031$ ). Thus, the NIE of treatment with alteplase on PSD was 0.82 (95% CI 0.67–0.99,  $p = 0.037$ ) and the controlled direct effect (CDE) was

(Continues)

**FIGURE 2** Percentage of patients with or without depression in both treatment groups for the composite end-point [Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]



**TABLE 2** Results of three multiple prediction models for the composite end-point of post-stroke depression (PSD)

	Main predictors (N = 438)		All predictors without transformed lesion volume (N = 420)		All predictors (N = 392)	
	OR (95% CI)	p value	OR (95% CI)	p value	OR (95% CI)	p value
Treatment with placebo (ref. alteplase)	1.58 (1.07, 2.34)	0.022	1.72 (1.13, 2.62)	0.012	1.70 (1.07, 2.68)	0.024
Age (per 10 years increase)	0.99 (0.83, 1.17)	0.882	0.99 (0.82, 1.18)	0.875	1.04 (0.85, 1.26)	0.727
NIHSS at baseline	1.13 (1.08, 1.18)	<0.001	1.12 (1.07, 1.17)	<0.001	1.05 (0.99, 1.11)	0.109
Male (ref. female)			1.12 (0.72, 1.75)	0.611	1.00 (0.62, 1.61)	0.995
Medication at baseline (ref. no)						
Antidepressant			4.55 (1.45, 14.31)	0.010	6.10 (1.72, 21.67)	0.005
Other psychiatric			1.64 (0.46, 5.92)	0.449	1.15 (0.30, 4.40)	0.843
History of depression (ref. no)			3.07 (0.70, 13.42)	0.135	6.54 (1.04, 41.17)	0.045
Hemisphere (ref. both hemispheres)						
Left hemisphere			0.55 (0.23, 1.33)	0.183	0.73 (0.29, 1.86)	0.511
Right hemisphere			0.63 (0.26, 1.55)	0.316	0.83 (0.32, 2.15)	0.705
Transformed lesion volume <sup>a</sup>					2.24 (1.62, 3.12)	<0.001

Abbreviations: CI, confidence interval; OR, odds ratio; NIHSS, National Institutes of Health Stroke Scale.

<sup>a</sup>Instead of the stroke lesion volume after 22–36 h, the base-2 logarithm of its third root was included in the model, such that the effect must be interpreted as a 2-fold increase of the stroke lesion length.

0.74 (95% CI 0.49–1.13,  $p = 0.162$ ). The effect of treatment on PSD is in our model referred to as the direct effect, in the sense that it is not mediated by the mRS.


After adjusting for age and NIHSS at baseline, the results changed slightly and the mediated path described 35% of the total effect (NIE 0.84, 95% CI 0.73–0.98,  $p = 0.027$  vs. CDE 0.73, 95% CI 0.48–1.10,  $p = 0.136$ ). Detailed results of the structural equation modelling are presented in Figure 4.

## DISCUSSION

In this post hoc analysis of the WAKE-UP trial, treatment with intravenous alteplase was associated with lower rates of PSD assessed at 90 days after stroke than placebo. Moreover, structural equation modelling revealed that the effect of intravenous alteplase on the reduction of depressive symptoms 90 days after stroke was only explained in part by the beneficial effect of alteplase on functional outcome defined by the mRS.

PSD is frequent after ischaemic stroke and has detrimental effects on functional outcome and dependence after stroke [21]. In our trial cohort, 33% of patients overall showed BDI values indicating depression at 90 days after stroke, and 48% of patients met the composite end-point of BDI values indicating depression, depression recorded as an SAE, or use of antidepressants. These numbers are rather high but within the range of reported prevalence rates of PSD 3 months after stroke and underline the importance of screening for PSD after stroke [22–24]. In a sensitivity analysis of an end-point of PSD which did not include medication with antidepressant, 41% of patients met the criteria of PSD, and the observed treatment effect of alteplase in reducing PSD at 90 days after stroke was comparable.

Intravenous thrombolysis with alteplase improves functional outcome after stroke, but the effects on PSD have not been reported in a randomized controlled trial. Given the fact that patients in the thrombolysis group presented with more severe strokes, comparable rates of PSD between patients receiving thrombolysis and those who did not receive thrombolysis were interpreted as possible indirect signs of a positive effect of thrombolysis on patients'




**FIGURE 3** Results of three multiple prediction models for the composite end-point of post-stroke depression (PSD).<sup>§</sup> Instead of the stroke lesion volume after 22–36 h, the base-2 logarithm of its third root was included in the model, such that the effect must be interpreted as a 2-fold increase of the stroke lesion length. The visualized confidence intervals are truncated at the value 16 [Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

mood after stroke [25]. Previous observational studies have pointed towards a possible beneficial effect of alteplase on PSD [7], but it was assumed that this was mediated by an indirect effect resulting from improved functional outcome with thrombolysis. In support of this, functional impairment was identified as a predictor of PSD in previous studies [26,27]. On the other hand, depressive symptoms were observed in a relevant proportion of patients with no or only minimal neurological deficit at 90 days after stroke [28], and this has been attributed to possible traumatic effects of stroke beyond resulting symptoms and disability which might not be modulated by thrombolysis [13].

In our study, treatment with intravenous alteplase resulted in an absolute risk reduction of PSD of 10.8% for the composite end-point of depression defined by the BDI, depression recorded as SAE, or the use of antidepressants. In other words, PSD can be averted in about one in 10 patients by treatment with alteplase. By the use of structural equation modelling analysis it was further possible to show that the effect of intravenous alteplase on PSD is not fully captured by the traditional measurement of functional outcome by the mRS. As expected based on the reported association of functional outcome

with PSD, a large part of the effect of alteplase treatment on symptoms of depression after 90 days can be explained by mRS values reflecting functional outcome at the time of assessment. However, more than half of the effect of intravenous alteplase on PSD was not captured by the mRS score at 90 days, shown by a direct effect of treatment with alteplase on PSD in our model. This effect was stable with and without adjustment for age and stroke severity. The potential mechanisms underlying this beneficial effect of thrombolysis on depressive symptoms after stroke can only be speculated on. A direct pharmacological effect of short-term acute treatment with recombinant tissue-plasminogen activator on mood 3 months later appears unlikely. So it is more likely to be the biological effects of alteplase, that is, reperfusion leading to salvage of brain tissue from final infarction, that may be responsible for the protective effect against PSD. This may include the prevention of symptoms or social and emotional consequences from stroke beyond those factors captured by the mRS at 90 days. As patients' symptoms regularly exceed symptoms captured by 'classical' outcome measures, patient-reported outcome measures including symptoms of depression should represent an essential part of future studies [29].

**FIGURE 4** Mediation model investigating the direct influence of treatment on the composite end-point of post-stroke depression (PSD) and the indirect path mediated through the mRS, including adjustment for age and NIHSS at baseline. (a) Structural equation model scheme to visualize the mediation model. (b) Results of the mediation model as controlled direct (treatment on PSD), natural indirect (treatment via mRS on PSD) and total effect [Colour figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]



Altogether, these results further corroborate the beneficial effects of intravenous thrombolysis as a standard treatment for acute ischaemic stroke, leading to better functional outcome and improved quality of life after stroke [11,12]. Since wake-up stroke and strokes in a larger time window are treated with thrombolysis as a consequence of recent studies [14,30], this has gained even more significance.

Given the high prevalence of PSD and its impact on functional outcome and quality of life after stroke, the identification of patients at risk of depressive symptoms after stroke is a clinical need. Previous studies that investigated PSD and its predictors accredited a significant effect to high NIHSS score on admission [31], which was confirmed in the statistical analysis of this study. Only when stroke lesion volume was added to the prediction model, NIHSS no longer predicted PSD, which may be explained by the fact that both parameters, NIHSS at baseline and stroke lesion volume, reflect stroke severity.

Other predictors that were discussed in the literature could be confirmed in this study as well, such as medication with antidepressants [9]. Lesion volume [32] has been identified as a predictor of PSD [33] and was also associated with PSD in our analysis. Recurrently named predictors of PSD include higher disability after stroke, history of depression, low social support, lower education and cognitive impairment [22,27,31,34] of which history of depression was supported by this study. Additionally, higher mRS was associated with higher BDI score, as shown previously [13]. Therefore, screening of stroke patients with regard to these is crucial to identify early patients at risk of PSD.

There are limitations to our study. Assessment of PSD at 3 months was available for 438 of 477 surviving patients (86.58%) available for follow-up at 90 days. It cannot be ruled out that the

more severely affected patients in particular did not respond, resulting in a potential bias that underestimated the prevalence of PSD in our sample. Moreover, the assessment of PSD primarily relied on a single, although standardized and well established, rating scale and did not involve psychiatric evaluation. For the assessment of PSD, a follow-up of 3 months may also be rather short. Additionally, depression was not measured at baseline. It was attempted to adjust by adding baseline antidepressant medication to the model but still patients with baseline depression might have been missed. Indications for prescription of baseline medication were not recorded. It cannot be excluded that some of the patients may have received antidepressants for other reasons than depression [35], but in a sensitivity analysis it could be shown that, even when using a composite end-point without including antidepressant medication, there was a significant treatment effect of alteplase on PSD. Also, pre-stroke cognitive status was not recorded and may have accounted for PSD. Finally, due to the upper age limit of 80 years in WAKE-UP the results of this analysis cannot be generalized to populations of very elderly stroke patients.

## CONCLUSION

In the randomized controlled WAKE-UP trial, after adjustment for age and stroke severity, intravenous alteplase resulted in a significant reduction of the proportion of patients with PSD 90 days after stroke. While about one-third of the effect of alteplase on PSD was mediated by improved functional outcome, almost two-thirds of the effect was independent of the beneficial effect of alteplase on the mRS. More severe strokes or larger stroke lesion volume, previous medication with an antidepressant, and history of depression were

predictors of PSD and might help screen for patients at risk of developing PSD.

## ACKNOWLEDGEMENTS

The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant.

Open Access funding enabled and organized by Projekt DEAL.  
WOA Institution: Universitätsklinikum Hamburg-Eppendorf  
Blended DEAL: Projekt DEAL

## DISCLOSURES

AK reports grants from the European Union 7th Framework Programme during the conduct of the study. BC reports grants from the European Union 7th Framework Programme during the conduct of the study and personal fees from Bayer Vital and Abbott, all outside the submitted work. CZS is supported by a research grant from Novo Nordisk, outside the submitted work. VT has received personal fees as consultant or lecturer from Boehringer-Ingelheim, outside the submitted work. MEn reports grant support from Bayer, the German Research Foundation (DFG), the German Federal Ministry of Education and Research (BMBF), the German Center for Neurodegenerative Diseases (DZNE), the German Center for Cardiovascular Research (DZHK), the European Union, Corona Foundation and Fondation Leducq; and fees paid to the Charité from Boehringer Ingelheim, Bristol-Myers Squibb, BMS/Pfizer, Daiichi Sankyo, Amgen, GlaxoSmithKlineGSK, Sanofi, Covidien, Ever, Novartis, all outside the submitted work. JBF reports consulting, lecture and advisory board fees from BioClinica, Cerevast, Artemida, Brainomix, Merck and Lundbeck as well as a grant from the German Federal Ministry of Education and Research (01EO0801 and 01EO01301), outside the submitted work. JBF is holding European Patent No. 17179320.01-1906. RL is a senior clinical investigator of FWO Flanders. KWM has participated in advisory boards for Boehringer Ingelheim. Boehringer Ingelheim supplies medication for the ATTEST-2 clinical trial, funded by the Stroke Association and British Heart Foundation, for which he is Chief Investigator. SP reports personal fees from Lundbeck, outside the submitted work. CG reports personal fees from Boehringer Ingelheim, outside the submitted work. GT reports personal fees as consultant or lecturer from Acandis, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Portola, Stryker, and research grants from Bayer, Federal Ministry for Economic Affairs and Energy (BMWi), Corona Foundation, German Research Foundation (DFG), Else Kröner-Fresenius Foundation, European Union (Horizon 2020), German Innovation Fund, all outside the submitted work. All remaining authors declare no competing interests.

## AUTHOR CONTRIBUTIONS

Alina Königsberg: Conceptualization (equal); data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); software (equal); validation (equal); visualization (equal); writing

original draft (equal); writing review and editing (equal). Susanne Sehner: Methodology (equal); software (equal). Sönke Arlt: Conceptualization (equal); supervision (equal). Bastian Cheng: Data curation (equal); software (equal). Claus Simonsen: Data curation (equal). Florent Boutitie: Data curation (equal); formal analysis (equal); methodology (equal). Joaquin Serena: Data curation (equal). Vincent Thijs: Data curation (equal). Martin Ebinger: Data curation (equal). Mathias Endres: Data curation (equal). Jochen B. Fiebach: Data curation (equal). Robin Lemmens: Data curation (equal). Keith W. Muir: Data curation (equal). Norbert Nighoghossian: Data curation (equal). Salvador Pedraza: Data curation (equal). Christian Gerloff: Data curation (equal); project administration (equal); supervision (equal). Götz Thomalla: Conceptualization (equal); data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); supervision (equal); writing review and editing (equal).

## DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## ORCID

Alina Königsberg  <https://orcid.org/0000-0003-2591-1807>

Norbert Nighoghossian  <https://orcid.org/0000-0003-0594-4409>

## REFERENCES

1. Towfighi A, Ovbiagele B, El Husseini N, et al. Poststroke depression: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2017;48(2):e30-e43.
2. Shi Y, Xiang Y, Yang Y, Zhang N, Wang S, Ungvari GS, et al. Depression after minor stroke: prevalence and predictors. *J Psychosom Res*. 2015;79(2):143-147. <https://doi.org/10.1016/j.jpsychores.2015.03.012>
3. Schöttke H, Giabbiconi CM. Post-stroke depression and post-stroke anxiety: prevalence and predictors. *Int Psychogeriatrics*. 2015;27(11):1805-1812.
4. Meng G, Ma X, Li L, et al. Predictors of early-onset post-ischemic stroke depression: a cross-sectional study. *BMC Neurol*. 2017;17(1):199.
5. Parikh RM, Robinson RG, Lipsey JR, Starkstein SE, Fedoroff JP, Price TR. The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. *Arch Neurol*. 1990;47(7):785-789. Available from: <http://archneur.jamanetwork.com/article.aspx?articleid=590221>
6. Mak KK, Kong WY, Mak A, Sharma VK, Ho RCM. Polymorphisms of the serotonin transporter gene and post-stroke depression: a meta-analysis. *J Neurol Neurosurg Psychiatry*. 2013;84(3):322-328.
7. Grabowska-Fudala B, Jaracz K, Górna K, Miechowicz I, Wojtasz I, Jaracz J, et al. Depressive symptoms in stroke patients treated and non-treated with intravenous thrombolytic therapy: a 1-year follow-up study. *J Neurol*. 2018;265(8):1891-1899. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29916129>
8. Ilut S, Stan A, Blesneag A, Vacaras V, Vesa S, Fodoreanu L. Factors that influence the severity of post-stroke depression. *J Med Life*. 2017;10(3):167-171. Available from <http://www.ncbi.nlm.nih.gov/pubmed/29075345> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5652262>
9. Mitchell AJ, Sheth B, Gill J, et al. Prevalence and predictors of post-stroke mood disorders: a meta-analysis and meta-regression of

- depression, anxiety and adjustment disorder. *Gen Hosp Psychiatry*. 2017;47:48-60. Available from: <https://www.sciencedirect.com/science/article/pii/S0163834317301433?via%3Dihub>
10. Lee E-J, Kim JS, Chang D-I, et al. Differences in therapeutic responses and factors affecting post-stroke depression at a later stage according to baseline depression. *J Stroke*. 2018;20(2):258-267. <https://doi.org/10.5853/jos.2017.02712>
  11. Lees KR, Emberson J, Blackwell L, et al. Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. *Stroke*. 2016;47(9):2373-2379.
  12. Sandercock P. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the Third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. *Lancet Neurol*. 2013;12(8):768-776. [https://doi.org/10.1016/S1474-4422\(13\)70130-3](https://doi.org/10.1016/S1474-4422(13)70130-3)
  13. Schwab-Malek S, Vatankeh B, Bogdahn U, Horn M, Audebert HJ. Depressive symptoms and quality of life after thrombolysis in stroke: the TEMPiS study. *J Neurol*. 2010;257(11):1848-1854.
  14. Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-guided thrombolysis for stroke with unknown time of onset. *N Engl J Med*. 2018;379(7):611-622. <https://doi.org/10.1056/NEJMoa1804355>
  15. Aben I, Verhey F, Lousberg R, Lodder J, Honig A. Validity of the Beck Depression Inventory, Hospital Anxiety and Depression Scale, SCL-90, and Hamilton Depression Rating Scale as screening instruments for depression in stroke patients. *Psychosomatics*. 2002;43(5):386-393. Available from <http://linkinghub.elsevier.com/retrieve/pii/S0033318202703666>
  16. Berg A, Lönnqvist J, Palomäki H, Kaste M. Assessment of depression after stroke: a comparison of different screening instruments. *Stroke*. 2009;40(2):523-529.
  17. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. *Stroke*. 2005;36(6):1330-1340.
  18. Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. *Psychol Methods*. 2010;15(4):309-334. Available from <http://www.ncbi.nlm.nih.gov/pubmed/20954780>
  19. Imai K, Keele L, Tingley D, Yamamoto T. Unpacking the black box of causality: learning about causal mechanisms from experimental and observational studies. *Am Polit Sci Rev*. 2011;105(4):765-789.
  20. Emsley R, Liu H. PARAMED: Stata module to perform causal mediation analysis using parametric regression models. *Stat Softw Components* S457581. 2013.
  21. Schmid AA, Kroenke K, Hendrie HC. Poststroke depression and treatment effects on functional outcomes. *Neurology*. 2011;76:1000-1005.
  22. Pohjasvaara T, Leppavuori A, Siira I, Vataja R, Kaste M, Erkinjuntti T. Frequency and clinical determinants of poststroke depression. *Stroke*. 1998;29(11):2311-2317. Available from <http://stroke.ahajournals.org/content/29/11/2311.abstract>
  23. Wei C, Zhang F, Chen L, Ma X, Zhang N, Hao J. Factors associated with post-stroke depression and fatigue: lesion location and coping styles. *J Neurol*. 2016;263(2):269-276.
  24. Vataja R, Leppävuori A, Pohjasvaara T, Mäntylä R, Aronen HJ, Salonen O, et al. Poststroke depression and lesion location revisited. *J Neuropsychiatry Clin Neurosci*. 2004;16(2):156-162. <https://doi.org/10.1176/appi.neuropsych.16.2.156>
  25. de Weerd L, Luijckx GJR, Groenier KH, van der Meer K. Quality of life of elderly ischaemic stroke patients one year after thrombolytic therapy. A comparison between patients with and without thrombolytic therapy. *BMC Neurol*. 2012;12(1):1.
  26. Karakus K, Kunt R, Memis CO, et al. The factors related to early-onset depression after first stroke. *Psychogeriatrics*. 2017;17(6):414-422. Available from <http://www.ncbi.nlm.nih.gov/pubmed/28387015>
  27. De Ryck A, Franssen E, Brouns R, Geurden M, Peij D, Mariën P, et al. Poststroke depression and its multifactorial nature: results from a prospective longitudinal study. *J Neurol Sci*. 2014;347(1-2):159-166. <https://doi.org/10.1016/j.jns.2014.09.038>
  28. Katzan IL, Thompson NR, Uchino K, Lapin B. The most affected health domains after ischemic stroke. *Neurology*. 2018;90(16):E1364-E1371.
  29. Reeves M, Lisabeth L, Williams L, et al. Patient-reported outcome measures (PROMs) for acute stroke: rationale, methods and future directions. *Stroke*. 2018;49(6):1549-1556.
  30. Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. *N Engl J Med*. 2019;380(19):1795-1803.
  31. Shi Y, Xiang Y, Yang Y, Zhang N, Wang S, Ungvari GS, et al. Depression after minor stroke: prevalence and predictors. *J Psychosom Res*. 2015;79(2):143-147. Available from <https://linkinghub.elsevier.com/retrieve/pii/S0022399915000860>
  32. Sharpe M, Hawton K, Seagroatt V, et al. Depressive disorders in long-term survivors of stroke. Associations with demographic and social factors, functional status, and brain lesion volume. *Br J Psychiatry*. 1994;164(3):380-386. <https://doi.org/10.1192/bjp.164.3.380>
  33. Vojtkiv-Samoilovska D, Arsovska A. Prevalence and predictors of depression after stroke—results from a prospective study. *Open Access Maced J Med Sci*. 2018;6(5):824-828.
  34. Salinas J, Beiser A, Himali JJ, Rosand J, Seshadri S, Dunn EC. Factors associated with new-onset depression after stroke. *J Neuropsychiatry Clin Neurosci*. 2016;28(4):286-291. <https://doi.org/10.1176/appi.neuropsych.15110388>
  35. Chollet F, Tardy J, Albucher J-F. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *Lancet Neurol*. 2011;10(2):123-130.

**How to cite this article:** Königsberg A, Sehner S, Arlt S, et al. Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial. *Eur J Neurol*. 2021;28:2017-2025. <https://doi.org/10.1111/ene.14797>